CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
About this item
Full title
Author / Creator
Su, Shu , Hu, Bian , Shao, Jie , Shen, Bin , Du, Juan , Du, Yinan , Zhou, Jiankui , Yu, Lixia , Zhang, Lianru , Chen, Fangjun , Sha, Huizi , Cheng, Lei , Meng, Fanyan , Zou, Zhengyun , Huang, Xingxu and Liu, Baorui
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Strategies that enhance the function of T cells are critical for immunotherapy. One negative regulator of T-cell activity is ligand PD-L1, which is expressed on dentritic cells (DCs) or some tumor cells and functions through binding of programmed death-1 (PD-1) receptor on activated T cells. Here we described for the first time a non-viral mediated...
Alternative Titles
Full title
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4730182
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4730182
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/srep20070
